Hester Biosciences Limited — Others, 09-05-2025: Appointment

Hester Biosciences has announced a board meeting on the approval of its audited standalone and consolidated financial results for the quarter and year ended March 31, 2025. Standalone revenue grew 5% in Q4 and 1% for FY25, driven by 8% growth in Animal Healthcare and 3% in Poultry Healthcare. Profit after tax rose 30% in Q4 and 17% for the year. Consolidated revenue increased 3% in Q4 and 2% for FY25, with profit up 36% for the full year despite a Q4 dip. A dividend of ₹7 per share is proposed. Shah & Shah Associates has been appointed Secretarial Auditor for five years starting FY26, subject to approval. The company is focusing on international expansion, new product launches, and expanding nutritional and therapeutic offerings to support growth.